Innovative Diagnostics Target Critical Drug Resistance February 18, 2026 | Santa Maria, California U.S. Food and Drug Administration has granted Breakthrough Device Designation to two rapid diagnostic assays developed by NG Biotech in partnership with Hardy Diagnostics, recognizing their potential to address life-threatening antimicrobial resistance threats. The designated tests—NG-TEST® Candida auris and NG-TEST® Acineto-5®—are designed to rapidly detect critical drug-resistant fungal and bacterial pathogens in clinical settings. The recognition underscores the urgent global need for faster diagnostic tools capable of strengthening infection control, surveillance, and treatment decision-making against multidrug-resistant organisms.
Science Significance
The two assays represent next-generation lateral flow immunoassay diagnostics engineered for rapid pathogen identification. NG-TEST® Candida auris is the first rapid immunoassay dedicated to detecting Candida auris, an emerging multidrug-resistant fungal pathogen associated with hospital outbreaks and high mortality. The test delivers results in approximately 15 minutes, demonstrating high detection reliability across multiple pathogen clades without cross-reactivity. NG-TEST® Acineto-5® is designed to detect and differentiate key carbapenemase enzymes in Acinetobacter species, including OXA-23, OXA-24/143, OXA-58, VIM, and NDM resistance markers. By enabling PCR-free detection with high sensitivity and specificity, the assay simplifies laboratory workflows while accelerating antimicrobial resistance monitoring.Together, the technologies highlight scientific progress in point-of-care microbiology and outbreak containment diagnostics.
Regulatory Significance
Breakthrough Device Designation is granted to technologies demonstrating potential to provide more effective diagnosis of life-threatening diseases. The status enables accelerated regulatory interaction, prioritized review pathways, and streamlined evidence development with the FDA. While the assays have not yet received 510(k) clearance and are currently available for research use only, the designation signals regulatory recognition of their clinical importance. From a cGxP perspective, progression toward commercialization will require robust design controls, validation studies, manufacturing quality systems, and compliance with device Quality Management System regulations. The designation therefore represents both regulatory validation and a pathway toward expedited market authorization.
Business Significance
Advertisement
Strategically, the dual designation strengthens the long-standing collaboration between NG Biotech and Hardy Diagnostics, with the latter serving as exclusive U.S. distributor. The recognition enhances commercial visibility, investor confidence, and partnership opportunities within the infectious disease diagnostics sector. Manufacturing operations based in France and ISO-certified quality systems position the companies for scalable production as regulatory clearance advances. Breakthrough status often accelerates product adoption, reimbursement alignment, and global distribution expansion, reinforcing competitive positioning in the rapidly growing antimicrobial resistance diagnostics market.
Patients’ Significance
For patients, rapid identification of multidrug-resistant organisms is critical to survival and treatment outcomes. Delayed or inaccurate diagnosis can lead to inappropriate antimicrobial therapy, prolonged hospitalization, and increased mortality risk. Faster detection of Candida auris and carbapenem-resistant Acinetobacter enables earlier targeted treatment, improved infection control, and reduced transmission in healthcare environments. Rapid diagnostics also support antimicrobial stewardship programs by minimizing unnecessary broad-spectrum antibiotic use.
Policy Significance
Antimicrobial resistance remains a top global public health priority, with the World Health Organization classifying both Candida auris and carbapenem-resistant Acinetobacter as critical threats. Breakthrough designation for these diagnostics aligns with international policy initiatives promoting early detection, outbreak surveillance, and AMR containment infrastructure. Governments and healthcare systems are increasingly investing in rapid testing technologies to strengthen preparedness against hospital-acquired infections and emerging resistant pathogens.
The FDA’s Breakthrough Device recognition of NG Biotech’s rapid AMR diagnostics marks a pivotal advancement in infectious disease detection. By combining speed, accuracy, and workflow simplicity, the assays have the potential to transform how healthcare systems identify and respond to drug-resistant outbreaks. As regulatory review progresses, these innovations are poised to play a critical role in global antimicrobial resistance mitigation, reinforcing the importance of diagnostic technology in safeguarding modern healthcare.
Source: Hardy Diagnostics NG Biotech press release
